Bazaar Updates
Closed · opens Mon 09:00 IST
Manage your watchlist and alerts here. Voting and comments need desktop.
Press ? for shortcuts
Report
Be the first to vote

Motilal Oswal initiates coverage on Molbio Diagnostics stock with Buy, sees 21% upside. Here's why ↗

Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, led by Molbio’s Truenat platform, which has 12,500+ devices across 90+ countries and 43 assays for 30 diseases.

From The Economic Times Markets

Read full story ↗

2 sources

  1. The Economic Times Markets · 6 Oct, 14:00 IST
  2. The Economic Times Stocks · 6 Oct, 14:00 IST

Open on desktop to take part.

0 comments

Comments are posted by users and are not reviewed by Bazaar Updates.

Open on desktop to take part.

No comments yet.